Recent Updates — SYRE
Spyre Therapeutics, Inc. entered into an underwriting agreement to sell 4,117,648 shares of common stock at a public offering price of $85.00 per share, generating approximately $350.0 million in gross proceeds. The company granted underwriters a 30-day option to purchase up to an additional 617,647 shares on the same terms. The offering is expected to close around October 7, 2026. Spyre intends to use the net proceeds to advance programs in gastroenterology, rheumatology, and dermatology, fund preclinical studies and clinical trials, support Phase 3 readiness for SPY072 in hidradenitis suppurativa, develop infrastructure, and potentially acquire or in-license new technologies. The company operates as a biopharmaceutical firm focused on developing novel therapies for inflammatory diseases.
Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial for SPY003, an anti-IL-23 antibody being investigated for moderately-to-severely active ulcerative colitis. The drug met its primary endpoint with a statistically significant 10.0-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001), alongside clinical remission and endoscopic improvement rates of 20% and 30%, respectively. This result establishes proof-of-concept for all three monotherapy components (SPY001, SPY002, and SPY003) in the company's inflammatory bowel disease portfolio. The filing confirms that Part B of the SKYLINE trial is actively enrolling combination arms, with topline induction data expected in 2027. Spyre Therapeutics operates as a clinical-stage biotechnology company developing next-generation immunology and inflammation therapies.
Spyre Therapeutics announced topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072. Both low and high doses demonstrated statistically significant benefits compared to placebo on primary or secondary endpoints, including DAS28-CRP and ACR20/ACR50 responses at Week 12. The drug was well-tolerated with a safety profile consistent with the TL1A class. However, the magnitude of efficacy did not meet the company's internal bar to prioritize SPY072 as a monotherapy in RA. The results provide proof-of-mechanism for TL1A inhibition and support its potential in other autoimmune diseases and as a combination component. Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation immunology therapies.
Spyre Therapeutics reported second quarter 2026 financial results on August 4, 2026, announcing a net loss of $36.2 million compared to $36.7 million in the prior year period. The company raised $435.2 million in net proceeds from a public offering of common stock in April 2026, resulting in a cash position of $1.1 billion as of June 30, 2026. Research and development expenses increased to $65.5 million from $40.1 million year-over-year due to higher manufacturing and clinical trial costs. The company also recognized a $40.0 million gain on the sale of in-process research and development assets related to pegzilarginase rights sold to Immedica Pharma AB. Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation immunology therapies for inflammatory bowel disease and rheumatic diseases.
Spyre Therapeutics announced positive 12-week induction topline data from Part A of its Phase 2 SKYLINE trial for SPY002, targeting moderately-to-severely active ulcerative colitis. The drug met its primary endpoint with a statistically significant 10.7-point reduction in the Robarts Histopathology Index (p<0.0001). Clinical remission was achieved in 33% of participants, and 42% showed endoscopic improvement. The safety profile was consistent with the TL1A class, with 41.7% of subjects experiencing any adverse event and two serious adverse events reported, both deemed not drug-related. Spyre Therapeutics is a biotechnology company developing therapies for inflammatory diseases.